IDEAYA Biosciences, Inc. (IDYA) stock
IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/307% below fair value
$26.49−0.91 (-3.32%)
Close on Nov 18, 2026Market cap $2.56BP/E –Yield –
IDEAYA Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
IDEAYA Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$216.95M. For fiscal 2025 it was -$159.31M. The highest annual figure on record is -$14.44M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$159.31M | – |
| FY2024 | Dec 31, 2024 | -$326.98M | – |
| FY2023 | Dec 31, 2023 | -$134.43M | – |
| FY2022 | Dec 31, 2022 | -$62.50M | – |
| FY2021 | Dec 31, 2021 | -$50.27M | – |
| FY2020 | Dec 31, 2020 | -$35.34M | – |
| FY2019 | Dec 31, 2019 | -$44.27M | – |
| FY2018 | Dec 31, 2018 | -$36.42M | – |
| FY2017 | Dec 31, 2017 | -$14.44M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$122.29M | – |
| Q1 FY2026 | Mar 31, 2026 | -$108.54M | – |
| Q4 FY2025 | Dec 31, 2025 | -$94.57M | – |
| Q3 FY2025 | Sep 30, 2025 | $108.45M | – |
| Q2 FY2025 | Jun 30, 2025 | -$88.81M | – |
| Q1 FY2025 | Mar 31, 2025 | -$84.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$144.14M | – |
| Q3 FY2024 | Sep 30, 2024 | -$66.89M | – |
| Q2 FY2024 | Jun 30, 2024 | -$64.93M | – |
| Q1 FY2024 | Mar 31, 2024 | -$51.02M | – |
| Q4 FY2023 | Dec 31, 2023 | -$41.92M | – |
| Q3 FY2023 | Sep 30, 2023 | -$33.53M | -5179.7% |
| Q2 FY2023 | Jun 30, 2023 | -$32.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.44M | – |
| Q3 FY2022 | Sep 30, 2022 | $660.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.50M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.22M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.37M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.71M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.05M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.28M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.00M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.59M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.48M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.32M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.62M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.24M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.09M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.13M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.63M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.57M | – |
See a number that looks wrong?